Xilio Therapeutics, Inc. (XLO) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $137.53M | +148.7% |
| 2024 | $55.29M | +23.7% |
| 2023 | $44.70M | -62.9% |
| 2022 | $120.39M | -39.2% |
| 2021 | $198.05M | +929.5% |
| 2020 | $19.24M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $137.53M | +148.7% |
| 2024 | $55.29M | +23.7% |
| 2023 | $44.70M | -62.9% |
| 2022 | $120.39M | -39.2% |
| 2021 | $198.05M | +929.5% |
| 2020 | $19.24M | — |